[go: up one dir, main page]

PE20020853A1 - Composiciones farmaceuticas, formas de dosificacion y metodos para la administracion oral de epotilonas - Google Patents

Composiciones farmaceuticas, formas de dosificacion y metodos para la administracion oral de epotilonas

Info

Publication number
PE20020853A1
PE20020853A1 PE2002000061A PE2002000061A PE20020853A1 PE 20020853 A1 PE20020853 A1 PE 20020853A1 PE 2002000061 A PE2002000061 A PE 2002000061A PE 2002000061 A PE2002000061 A PE 2002000061A PE 20020853 A1 PE20020853 A1 PE 20020853A1
Authority
PE
Peru
Prior art keywords
alkyl
epotilones
heterocycle
methods
pharmaceutical compositions
Prior art date
Application number
PE2002000061A
Other languages
English (en)
Inventor
Rebanta Bandyopadhyay
Krishnaswamy Srinivas Raghavan
Sailesh Amilal Varia
Timothy M Malloy
Andrea Panaggio
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20020853A1 publication Critical patent/PE20020853A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UN METODO PARA AUMENTAR LA BIODISPONIBILIDAD DE EPOTILONOS DE FORMULA I, II, ADMINISTRADOS ORALMENTE; DONDE G ES ALQUILO, ARIL, HETEROCICLO; R8HC=C(R9)-, DR10HC-; (R11)(R12)N-C(O)-, W ES O, NR16; X ES O, S, CHR17, H, R18; Y ES H, H; H, OR22; OR23, OR23; NOR24; NOR25, NHNR28R29, NHNR30, CHR32, ENTRE OTROS; B1 Y B2 SON H, OR33, OCOR34; OCONR35R36, NR37R38; D ES NR42R43, HETEROCICLO; R1, R2, R3, R4, R5 SON H, ALQUILO; R8, R9, R10, R11 SON H, ALQUILO, ARIL, CICLOALQUILO, HETEROCICLO; R17, R18, R22, R23 SON H, ALQUILO; R24, R25, R26, R28, R30, R32, R33, R34, R35, R36, R37, R39, R40, R41, R42, R51, R52, R53, R61 SON H, ALQUILO, ARIL; R12, R16, R27, R29, R31, R38, R43 SON H, ALQUILO, ARIL, CICLOALQUILO, HETEROCICLO, R51, CO; R52OCO, R53SO2, HIDROXI, O-ALQUILO Y UN BUFFER TAL COMO FOSFATO DE SODIO DIBASICO ANHIDRO, DIHIDRATO CITRATO DE SODIO, ACIDO CITRICO ANHIDRO CON UN pH DE 5 A 9 SIENDO EL SOLVENTE RECONSTITUYENTE UNA MEZCLA DE PROPILENGLICOL Y ETANOL. TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE DE 0,05mg A 200mg DE EPOTILONO, BUFFER. UN COMPUESTO PREFERIDO [1S-[1R*,3R*(E),7R*,10S*,11R*,16S*]]-7,11-DIHIDROXI-8,8,10,12,16-PENTAETIL-3-[1-METIL-2-(2-METIL-4-TIAZOL)ETENIL-17-OXA-4-AZABICICLO[14.1.0]HEPTADECANO-5,9-DIONA
PE2002000061A 2001-01-25 2002-01-25 Composiciones farmaceuticas, formas de dosificacion y metodos para la administracion oral de epotilonas PE20020853A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26422801P 2001-01-25 2001-01-25
US29001901P 2001-05-11 2001-05-11

Publications (1)

Publication Number Publication Date
PE20020853A1 true PE20020853A1 (es) 2002-09-27

Family

ID=26950349

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000061A PE20020853A1 (es) 2001-01-25 2002-01-25 Composiciones farmaceuticas, formas de dosificacion y metodos para la administracion oral de epotilonas

Country Status (26)

Country Link
US (2) US6576651B2 (es)
EP (1) EP1361877A1 (es)
JP (1) JP2004528287A (es)
KR (1) KR20040025888A (es)
CN (1) CN1268336C (es)
AR (1) AR035078A1 (es)
BG (1) BG108027A (es)
BR (1) BR0206695A (es)
CA (1) CA2434584A1 (es)
CZ (1) CZ20032023A3 (es)
EE (1) EE200300329A (es)
HR (1) HRP20030674A2 (es)
HU (1) HUP0303800A3 (es)
IL (1) IL156759A0 (es)
IS (1) IS6892A (es)
MX (1) MXPA03006476A (es)
NO (1) NO20033343L (es)
NZ (1) NZ526871A (es)
PE (1) PE20020853A1 (es)
PL (1) PL368636A1 (es)
RU (1) RU2291695C2 (es)
SK (1) SK9212003A3 (es)
TW (1) TWI250017B (es)
UY (1) UY27138A1 (es)
WO (2) WO2002058699A1 (es)
YU (1) YU58103A (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001124A1 (en) * 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
CA2374944A1 (en) 1999-06-10 2000-12-21 Nigel Hacker Spin-on-glass anti-reflective coatings for photolithography
US6824879B2 (en) 1999-06-10 2004-11-30 Honeywell International Inc. Spin-on-glass anti-reflective coatings for photolithography
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
CA2434566A1 (en) * 2001-01-25 2002-08-15 Timothy M. Malloy Parenteral formulation containing epothilone analogs
PL363362A1 (en) 2001-02-20 2004-11-15 Bristol-Myers Squibb Company Treatment of refractory tumors using epothilone derivatives
EP1383490B1 (en) * 2001-03-14 2012-04-25 Bristol-Myers Squibb Company Combination of an epothilone analog and chemotherapeutic agents for the treatment of proliferative diseases
JP4381143B2 (ja) 2001-11-15 2009-12-09 ハネウェル・インターナショナル・インコーポレーテッド フォトリソグラフィー用スピンオン反射防止膜
WO2003077903A1 (en) * 2002-03-12 2003-09-25 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
ATE450534T1 (de) 2002-08-23 2009-12-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte davon, analoga und ihre verwendung
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO2004032866A2 (en) * 2002-10-09 2004-04-22 Kosan Biosciences, Inc. Therapeutic formulations
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
HUE029382T2 (en) * 2003-08-26 2017-02-28 Shire Biopharmaceuticals Holdings Ireland Ltd Pharmaceutical composition containing lanthanum compounds
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
AU2004291107B2 (en) * 2003-11-14 2010-09-30 Brigham And Women's Hospital, Inc. Methods of modulating immunity
US8053159B2 (en) 2003-11-18 2011-11-08 Honeywell International Inc. Antireflective coatings for via fill and photolithography applications and methods of preparation thereof
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
US20060069136A1 (en) * 2004-09-24 2006-03-30 Ulrich Klar Use of Epothilones in the treatment of bone metastasis
KR20070084325A (ko) * 2004-11-18 2007-08-24 브리스톨-마이어스 스큅 컴퍼니 익사베필론을 포함하는 장용성 코팅된 비드 및 그의 제조방법
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US8642246B2 (en) 2007-02-26 2014-02-04 Honeywell International Inc. Compositions, coatings and films for tri-layer patterning applications and methods of preparation thereof
CL2009000990A1 (es) 2008-04-24 2010-10-15 Bristol Myers Squibb Co Uso de epotilona d para el tratamiento de enfermedades asociadas a tau, tal como enfermedad alzheimer, parkinson, entre otras.
US8557877B2 (en) 2009-06-10 2013-10-15 Honeywell International Inc. Anti-reflective coatings for optically transparent substrates
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
US8864898B2 (en) 2011-05-31 2014-10-21 Honeywell International Inc. Coating formulations for optical elements
CN102276433B (zh) * 2011-06-30 2016-04-20 南昌大学 木豆素c及其衍生物及其在制备抗癌药物中的应用
JP6803842B2 (ja) 2015-04-13 2020-12-23 ハネウェル・インターナショナル・インコーポレーテッドＨｏｎｅｙｗｅｌｌ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃ． オプトエレクトロニクス用途のためのポリシロキサン製剤及びコーティング

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
DK0873341T3 (da) 1995-11-17 2004-01-19 Biotechnolog Forschung Gmbh Epothilonderivater, fremstilling og anvendelse
PL189698B1 (pl) * 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19636343C1 (de) * 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
JP2001500851A (ja) 1996-08-30 2001-01-23 ノバルティス アクチエンゲゼルシャフト エポシロンの製造法および製造過程中に得られる中間生産物
WO1998022461A1 (de) 1996-11-18 1998-05-28 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO1999001124A1 (en) * 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
DE59805110D1 (de) 1997-02-25 2002-09-12 Biotechnolog Forschung Gmbh Seitenkettenmodifizierte epothilone
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
JP4065573B2 (ja) 1997-04-18 2008-03-26 ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 反応媒体として圧縮二酸化炭素中における二官能性または多官能性基質の選択的オレフィンメタセシス
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
EP1001951B1 (de) 1997-07-16 2002-09-25 Schering Aktiengesellschaft Thiazolderivate, verfahren zur herstellung und verwendung
CA2299608A1 (en) 1997-08-09 1999-02-18 Schering Aktiengesellschaft New epothilone derivatives, method for producing same and their pharmaceutical use
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
BR9907647B1 (pt) 1998-02-05 2014-04-01 Novartis Ag Novartis S A Novartis Inc Formulação farmacêutica na forma de um concentrado para infusão, o qual deve ser diluído antes da administração, e solução para infusão
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
EP1058679B1 (en) 1998-02-25 2005-10-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues therof
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
WO2000000485A1 (de) 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
CN100381566C (zh) 1998-11-20 2008-04-16 科森生物科学公司 产生环氧噻酮及其衍生物的重组方法和材料
ES2207983T3 (es) 1998-12-22 2004-06-01 Novartis Ag Derivados de epotilona y su uso como agentes antitumorales.
DE50014587D1 (de) 1999-02-18 2007-10-04 Bayer Schering Pharma Ag 16-halogen-epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
PE20010116A1 (es) 1999-04-30 2001-02-15 Schering Ag Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion
IL156578A0 (en) 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for pharmaceutical use and pharmaceutical preparations including an epothilone analog
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
EP1383490B1 (en) 2001-03-14 2012-04-25 Bristol-Myers Squibb Company Combination of an epothilone analog and chemotherapeutic agents for the treatment of proliferative diseases

Also Published As

Publication number Publication date
CN1268336C (zh) 2006-08-09
WO2002058701A1 (en) 2002-08-01
RU2291695C2 (ru) 2007-01-20
BG108027A (bg) 2004-12-30
CN1498106A (zh) 2004-05-19
HRP20030674A2 (en) 2005-06-30
BR0206695A (pt) 2004-04-20
KR20040025888A (ko) 2004-03-26
US6576651B2 (en) 2003-06-10
CZ20032023A3 (cs) 2005-03-16
HUP0303800A3 (en) 2005-02-28
NZ526871A (en) 2006-01-27
MXPA03006476A (es) 2003-09-22
RU2003126174A (ru) 2005-02-27
JP2004528287A (ja) 2004-09-16
TWI250017B (en) 2006-03-01
CA2434584A1 (en) 2002-08-01
YU58103A (sh) 2006-03-03
EE200300329A (et) 2003-10-15
US20020177615A1 (en) 2002-11-28
AR035078A1 (es) 2004-04-14
SK9212003A3 (en) 2004-11-03
EP1361877A1 (en) 2003-11-19
IL156759A0 (en) 2004-02-08
AU2002253880B2 (en) 2006-11-09
PL368636A1 (en) 2005-04-04
NO20033343L (no) 2003-09-24
NO20033343D0 (no) 2003-07-24
HUP0303800A2 (hu) 2004-03-29
WO2002058699A1 (en) 2002-08-01
UY27138A1 (es) 2002-08-30
IS6892A (is) 2003-07-24
USRE40387E1 (en) 2008-06-17

Similar Documents

Publication Publication Date Title
PE20020853A1 (es) Composiciones farmaceuticas, formas de dosificacion y metodos para la administracion oral de epotilonas
KR100884575B1 (ko) 미노시클린 함유 조성물
ES2566973T3 (es) Uso de SNS-595 para tratar leucemia
ES2096781T3 (es) Composiciones de oxicodones de liberacion controlada.
KR101052705B1 (ko) 아미노글리코시드계 항생물질 및 브롬페낙을 함유하는수용액 제제
AR006598A1 (es) "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
JPH0597668A (ja) 歯周炎の治療
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
MEP10808A (en) Solid drug for oral use
HU230738B1 (hu) Ketotifén tartalmú szemészeti készítmény
EP1782816B1 (en) Water-based medicinal composition containing azithromycin and method of preparing the same
MX2007006635A (es) Formulacion farmaceutica de inhibidores dela carboxamida vih integrasa que contienen una composicion que controla la velocidad de liberacion.
CZ281599B6 (cs) Farmaceutické prostředky s obsahem ranitidinu
IL92799A0 (en) Benzimidazole derivatives with gastric acid inhibition and process for its preparation
ES2197781A1 (es) Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno.
AR024411A1 (es) Polimorfos de un diclorhidrato cristalino de azobiciclo[2.2.2]oct-3-ilamina y sus composiciones farmaceuticas.
NO20061018L (no) Nytt preparat
YU81101A (sh) Polimorfni oblici kristalnog citrata azabiciklo (2,2,2) oktan-3-amina i njihovih farmaceutskih kompozicija
JP4799957B2 (ja) 口内炎の治療のための医薬組成物
JPH0234325B2 (ja) Shishushitsukanchiryoyososeibutsu
MX9803275A (es) Composiciones farmaceuticas que contienen inhibidores de agregacion de plaquetas.
GB2635282A8 (en) An oral liquid formulation of apixaban
WO2022244968A1 (ko) 벤지다민염산염을 포함하는 안정성이 개선된 가글액
AR133391A1 (es) Radiofármacos dirigidos a psma para el tratamiento del cáncer
JP2017066126A (ja) 口腔粘膜投与用の唾液分泌促進用医薬組成物

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed